OncoSphere AI was evaluated in a validation study presented at the ASCO 2026 Annual Meeting. Performance was assessed via built-in telemetry (task completion, latency, inter-agent agreement) and blinded review by eight expert oncologists using a structured survey rating data-extraction fidelity, guideline concordance, safety, and clinical utility versus standard manual review.
Key results
Study cohort
The cohort comprised 20 cases (median age 59.5 years; 55% female) with a median of 2.5 prior lines of therapy and multi-organ metastatic disease (median 2 organs involved) — spanning lung, breast, gastrointestinal (colorectal, pancreatic, hepatobiliary), and genitourinary (prostate, renal) malignancies. This is a deliberately difficult, heavily pretreated population.
Safety
Blinded safety review identified a single critical contraindication issue, in a heavily pretreated, multi-line setting. OncoSphere AI is advisory clinical decision support: every recommendation is reviewed by the treating physician, who makes the final decision.
What it means
OncoSphere AI consistently transformed heterogeneous longitudinal data into decision-grade insights with high fidelity and marked time savings — by operating as a coordinated ensemble of domain-specialized agents rather than a single generic model. It offers a scalable way to reduce physician cognitive burden and to standardize guideline-concordant care planning, including in diverse, heavily pretreated populations.
Citation: Desai A, McNeeley E, Alhushki S, et al. OncoSphere AI: An agentic AI multidisciplinary clinical workflow support tool. J Clin Oncol. 2026;44(16_suppl):e13656.
Read the abstract on ascopubs.org →